

**FORWARDHEALTH  
PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL)  
FOR MULTIPLE SCLEROSIS (MS) AGENTS, IMMUNOMODULATORS**

**Instructions:** Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Multiple Sclerosis (MS) Agents, Immunomodulators Completion Instructions, F-00805A. Providers may refer to the Forms page of the ForwardHealth Portal at [www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage](http://www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage) for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Multiple Sclerosis (MS) Agents, Immunomodulators form signed by the prescriber before submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at (800) 947-9627 with questions.

---

**SECTION I — MEMBER INFORMATION**

---

1. Name — Member (Last, First, Middle Initial)

2. Member Identification Number

3. Date of Birth — Member

---

**SECTION II — PRESCRIPTION INFORMATION**

---

4. Drug Name

5. Drug Strength

6. Date Prescription Written

7. Refills

8. Directions for Use

9. Name — Prescriber

10. National Provider Identifier — Prescriber

11. Address — Prescriber (Street, City, State, ZIP+4 Code)

12. Telephone Number — Prescriber

---

**SECTION III — CLINICAL INFORMATION (Required for all PA requests.)**

---

13. Diagnosis Code and Description

14. List the member's current MS immunomodulator therapy or check "none" if appropriate.

None

Drug Name \_\_\_\_\_ Daily Dose \_\_\_\_\_ Start Date \_\_\_\_\_

Drug Name \_\_\_\_\_ Daily Dose \_\_\_\_\_ Start Date \_\_\_\_\_

*Continued*



---

**SECTION III — CLINICAL INFORMATION (Required for all PA requests.) (Continued)**

---

15. List the member's previous MS immunomodulator therapy and reason(s) for discontinuation or check "none" if appropriate.

None

Drug Name \_\_\_\_\_ Daily Dose \_\_\_\_\_ Dates Taken \_\_\_\_\_

Reason for Discontinuation \_\_\_\_\_

Drug Name \_\_\_\_\_ Daily Dose \_\_\_\_\_ Dates Taken \_\_\_\_\_

Reason for Discontinuation \_\_\_\_\_

Drug Name \_\_\_\_\_ Daily Dose \_\_\_\_\_ Dates Taken \_\_\_\_\_

Reason for Discontinuation \_\_\_\_\_

---

**SECTION IV — CLINICAL INFORMATION FOR NON-PREFERRED ORAL MS IMMUNOMODULATORS**

---

16. Prior authorization requests must include detailed documentation regarding why the member is unable to take the preferred agents, including both Copaxone® **and** an MS interferon. Medical records should be provided as necessary to support the use of a non-preferred oral agent. The following will **not** be considered as criteria for use of a non-preferred oral agent:

- Non-adherence to previous MS treatment.
- The member's fear of needles.
- Member or prescriber preference for the use of an oral agent.

Copaxone® Documentation

MS Interferon Documentation

---

**SECTION V — CLINICAL INFORMATION FOR COPAXONE® 40 MG**

---

17. Prior authorization requests for Copaxone® 40 mg must include detailed documentation regarding why the member is unable to take Copaxone® 20 mg. Medical records should be provided, as necessary, to support the need for Copaxone® 40 mg. Non-adherence to previous MS treatment will not be considered as a criterion prohibiting the use of the preferred agent, Copaxone® 20 mg. In addition, member or prescriber preference for Copaxone® 40 mg will not be considered as a criterion prohibiting the use of the preferred agent, Copaxone® 20 mg.

---

**SECTION VI — AUTHORIZED SIGNATURE**

---

18. **SIGNATURE** — Prescriber

19. Date Signed

---

**SECTION VII — ADDITIONAL INFORMATION**

---

20. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here.

---